Robert J Slack

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action
    Robert J Slack
    Respiratory TAU, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
    J Pharmacol Exp Ther 344:218-30. 2013
  2. ncbi In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine
    Robert J Slack
    Respiratory CEDD Biology, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, UK
    Eur J Pharmacol 670:586-92. 2011
  3. ncbi Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists
    Panayiotis A Procopiou
    Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    Bioorg Med Chem 20:6097-108. 2012
  4. ncbi Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation
    Panayiotis A Procopiou
    Department of Medicinal Chemistry, Respiratory CEDD, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
    Bioorg Med Chem Lett 22:2730-3. 2012
  5. ncbi The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis
    Panayiotis A Procopiou
    Department of Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
    J Med Chem 54:2183-95. 2011

Detail Information

Publications5

  1. ncbi In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action
    Robert J Slack
    Respiratory TAU, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
    J Pharmacol Exp Ther 344:218-30. 2013
    ..This pharmacological profile combined with clinical data is consistent with once a day dosing of vilanterol in the treatment of both asthma and chronic obstructive pulmonary disease (COPD)...
  2. ncbi In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine
    Robert J Slack
    Respiratory CEDD Biology, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, UK
    Eur J Pharmacol 670:586-92. 2011
    ..These studies indicate there is a tissue component contributing to azelastine's duration of action, in addition to its direct H₁ receptor binding, with evidence suggesting a role for the epithelial layer...
  3. ncbi Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists
    Panayiotis A Procopiou
    Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    Bioorg Med Chem 20:6097-108. 2012
    ..The pharmacological profile of 44 was very similar to our intranasal clinical candidate 1...
  4. ncbi Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation
    Panayiotis A Procopiou
    Department of Medicinal Chemistry, Respiratory CEDD, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
    Bioorg Med Chem Lett 22:2730-3. 2012
    ..Synthesis and preliminary SAR of the N1 substituent of a novel series of indazole sulfonamide chemokine receptor 4 (CCR4) antagonist is reported. Compound 7r was identified for further development...
  5. ncbi The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis
    Panayiotis A Procopiou
    Department of Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
    J Med Chem 54:2183-95. 2011
    ....